Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Association’s 83rd Annual Scientific Sessions
22 Mai 2023 - 10:05PM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule product candidates to address serious
diseases, including oncology, non-alcoholic steatohepatitis (NASH)
and obesity, today announced that new preclinical data from a
transgenic mouse model evaluating TERN-601, a novel oral GLP-1R
agonist, has been accepted for poster presentation at the American
Diabetes Association’s 83rd Annual Scientific Sessions taking place
June 23-26, 2023 in San Diego, California. The abstract will also
be published online on the journal Diabetes® website.
Following are details of the upcoming
presentation:
Abstract Title: |
TERN-601, a novel oral GLP-1R agonist, suppresses food intake and
improves glucose tolerance in transgenic mice expressing human
GLP-1 receptor |
Presenter: |
Olivia Osborn, Director of
Biology, Terns Pharmaceuticals |
Poster Session
Date/Time: |
Sunday, June 25, 2023 from 11:30
AM-12:30 PM PT |
|
|
“We are excited to present these data before an
audience of world leading endocrinologists,” said Sen Sundaram,
chief executive officer at Terns. “Obesity is a growing epidemic
and GLP-1 agonists have demonstrated broad metabolic benefits in
obesity and Type 2 diabetes in clinical trials. Unfortunately, they
are often limited by injectable dosing, poor tolerability and cost
concerns. We believe TERN-601 has the potential to provide an
alternative that is safe, effective and affordable with the
convenience of a once-a-day tablet.”
As a reminder, all information contained in the
submitted abstract should be considered preliminary and subject to
change until the study is fully presented at the 83rd Scientific
Sessions. All information is subject to embargo until Friday, June
23, 2023 at 6:30pm PT.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule product candidates to
address serious diseases, including oncology, NASH and obesity.
Terns’ pipeline includes two clinical stage development programs
including an allosteric BCR-ABL inhibitor and a THR-β agonist (+/-
an FXR agonist), and preclinical small-molecule GLP-1 receptor
agonist and GIPR modulator programs. For more information, please
visit: www.ternspharma.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Terns Pharmaceuticals, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s expectations of timing and
potential results of the clinical trials and other development
activities of the Company and its partners; the potential
indications to be targeted by the Company with its small-molecule
product candidates; the therapeutic potential of the Company’s
small-molecule product candidates; the potential for the mechanisms
of action of the Company’s product candidates to be therapeutic
targets for their targeted indications; the potential utility and
progress of the Company’s product candidates in their targeted
indications, including the clinical utility of the data from and
the endpoints used in the Company’s clinical trials; the Company’s
clinical development plans and activities, including the results of
any interactions with regulatory authorities on its programs; the
Company’s expectations regarding the profile of its product
candidates, including efficacy, tolerability, safety, metabolic
stability and pharmacokinetic profile and potential differentiation
as compared to other products or product candidates; the Company’s
plans for and ability to continue to execute on its current
development strategy, including potential combinations involving
multiple product candidates; the impact of new legislation and
regulatory developments on the Company’s plans for its product
candidates, such as the effect of the Inflation Reduction Act of
2022; and the Company’s expectations with regard to its cash runway
and sufficiency of its cash resources. All statements other than
statements of historical facts contained in this press release,
including statements regarding the Company’s strategy, future
financial condition, future operations, future trial results,
projected costs, prospects, plans, objectives of management and
expected market growth, are forward-looking statements. In some
cases, you can identify forward-looking statements by terminology
such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,”
“continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,”
“intend,” “may,” “objective,” “plan,” “positioned,” “potential,”
“predict,” “seek,” “should,” “target,” “will,” “would” and other
similar expressions that are predictions of or indicate future
events and future trends, or the negative of these terms or other
comparable terminology. The Company has based these forward-looking
statements largely on its current expectations, estimates,
forecasts and projections about future events and financial trends
that it believes may affect its financial condition, results of
operations, business strategy and financial needs. In light of the
significant uncertainties in these forward-looking statements, you
should not rely upon forward-looking statements as predictions of
future events. These statements are subject to risks and
uncertainties that could cause the actual results and the
implementation of the Company’s plans to vary materially, including
the risks associated with the initiation, cost, timing, progress,
results and utility of the Company’s current and future research
and development activities and preclinical studies and clinical
trials. These risks are not exhaustive. For a detailed discussion
of the risk factors that could affect the Company’s actual results,
please refer to the risk factors identified in the Company’s SEC
reports, including but not limited to its Annual Report on Form
10-K for the year ended December 31, 2022. Except as required by
law, the Company undertakes no obligation to update publicly any
forward-looking statements for any reason.
Contacts for Terns
InvestorsJustin
Nginvestors@ternspharma.com
MediaJenna UrbanBerry &
Company Public Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024